Cardiokol Company Profile

Background

Company Overview

Cardiokol, established in 2017, is a privately-owned digital telehealth company headquartered in Airport City, Israel. The company specializes in developing voice-based markers and methods for monitoring and screening heart rhythm disorders, particularly atrial fibrillation (AF), in large at-risk populations. By leveraging proprietary technology integrated into speech platforms such as landlines, smartphones, smart speakers, and voice assistants, Cardiokol aims to facilitate early diagnosis and preventive care.

Mission and Vision

Cardiokol's mission is to enable mass prevention of strokes and chronic complications over time in at-risk populations using voice-based markers for telemonitoring and screening. The company's vision is to provide revolutionary, affordable, scalable, long-term, and age-friendly monitoring solutions applicable to mass at-risk populations, including older adults (65+).

Key Strategic Focus

Core Objectives

Early Detection of Atrial Fibrillation: Utilizing voice analysis to identify AF in asymptomatic individuals, thereby reducing the risk of stroke and other complications.

Scalable Monitoring Solutions: Implementing technology that allows for widespread, long-term monitoring without the need for additional hardware.

Areas of Specialization

Voice-Based Biomarkers: Developing algorithms that extract and identify vocal parameters associated with irregular heartbeats.

Telehealth Integration: Embedding proprietary technology into existing speech platforms to facilitate seamless monitoring.

Key Technologies Utilized

Signal Processing Techniques: Analyzing voice signals to detect anomalies indicative of AF.

Artificial Intelligence: Employing neural network models trained on clinical databases of AF and normal heart rhythm vocal recordings.

Primary Markets Targeted

Older Adults (65+): Focusing on age-friendly solutions that do not require wearable devices.

Healthcare Providers and Insurers: Collaborating with entities interested in cost-effective, scalable monitoring solutions.

Financials and Funding

Funding History

Seed Round (September 2019): Raised $8 million from Kamet Ventures and individual investors.

Accelerator/Incubator Programs (2021-2022): Participated in programs such as Bayer's G4A Partnerships Program, receiving funding and mentorship.

Intended Utilization of Capital

Technology Development: Enhancing proprietary algorithms and expanding the range of detectable conditions.

Clinical Trials: Conducting studies to validate technology efficacy and obtain regulatory approvals.

Market Expansion: Extending operations into new geographical regions and forming strategic partnerships.

Pipeline Development

Key Pipeline Candidates

Voice-Based AF Detection Application: A software solution integrated into various speech platforms for the detection of atrial fibrillation.

Stages of Development

Clinical Trials: Completed studies involving 700 patients, with further trials planned in Europe and the United States.

Target Conditions

Atrial Fibrillation: Focusing on early detection to prevent strokes and other complications.

Anticipated Milestones

Regulatory Approvals: Achieved in Europe and Israel; pursuing approvals in additional regions.

Commercial Agreements: Ongoing discussions with pharmaceutical companies and healthcare providers.

Technological Platform and Innovation

Proprietary Technologies

Voice Analysis Algorithms: Extracting vocal parameters to detect irregular heart rhythms.

Neural Network Models: Trained on extensive clinical databases to enhance detection accuracy.

Significant Scientific Methods

Signal Processing: Analyzing voice signals to identify anomalies associated with AF.

Machine Learning: Utilizing AI to improve detection capabilities and reduce false positives.

Leadership Team

Executive Profiles

James Amihood, Co-founder & CEO: Over 25 years of management experience, including roles at PRM Inc., Syqe Medical, and multinational pharmaceutical companies.

Alon Goren, Executive Chairman & Co-founder: Experienced innovator and entrepreneur, founder and former CEO of Endymed.

Yirmi Hauptman, CTO & Co-founder: Over 20 years of experience in signal processing of speech signals, including medical applications.

Eli Attar, COO, VP R&D & Co-founder: Over 20 years as a technology and engineering executive in telecom companies and mega projects.

Pini Sabach, Co-founder, Chief Collaborations & Cyber Security Officer: Experienced in various entrepreneurial and management positions.

Leadership Changes

No recent significant changes or appointments within the company's leadership have been reported.

Competitor Profile

Market Insights and Dynamics

Market Size and Growth Potential: The global atrial fibrillation market is expanding due to the increasing prevalence of AF and the demand for non-invasive monitoring solutions.

Industry Trends: There is a growing emphasis on telehealth solutions and AI-driven diagnostics in the healthcare industry.

Competitor Analysis

Coala Life: Offers ECG-based heart monitoring solutions.

AliveCor: Provides mobile ECG devices for heart rhythm monitoring.

CardioSignal: Develops smartphone-based heart monitoring applications.

Competitive Landscape

Cardiokol differentiates itself by offering a hardware-free, voice-based solution that is cost-effective, scalable, and age-friendly, addressing the limitations of wearable devices and manual ECG recordings.

Strategic Collaborations and Partnerships

Significant Collaborations

Bayer's G4A Partnerships Program: Selected as a finalist, receiving funding and mentorship.

Kamet Ventures: Participated in funding rounds and provided strategic support.

Impact on Market Position

These collaborations have enhanced Cardiokol's credibility, provided financial resources, and facilitated access to broader markets.

Operational Insights

Strategic Considerations

Market Position: Cardiokol's unique voice-based technology positions it as a leader in non-invasive AF detection.

Competitive Advantages: The company's solutions are hardware-free, cost-effective, and suitable for large-scale, long-term monitoring, particularly in older populations.

Strategic Opportunities and Future Directions

Strategic Roadmap

Technology Enhancement: Expanding the range of detectable conditions beyond AF.

Geographical Expansion: Entering new markets through regulatory approvals and partnerships.

Product Diversification: Developing additional applications for voice-based health monitoring.

Opportunities for Expansion

Telehealth Integration: Collaborating with telehealth providers to embed technology into existing platforms.

Insurance Partnerships: Working with insurers to offer preventive monitoring solutions to policyholders.

Positioning for Future Objectives

Cardiokol's strengths in innovative technology, strategic partnerships, and focus on scalable solutions position the company to achieve its objectives in expanding access to non-invasive heart rhythm monitoring.